The aim of this cross-sectional study was to determine the prevalence of metabolic syndrome (MetS) and its components among 100 patients with progressive peripheral arterial disease (PAD) referred for diagnostic angiography in preparation for a revascularization procedure. The prevalence of MetS was more than 95%. Diabetes mellitus was the most prevalent component followed by hypertension and low high-density lipoprotein. Almost half the patients aggregated in the highest metabolic score category. A direct relationship was identified between the number of MetS components and serum uric acid (P = .001) and C-reactive protein (P = .826), whereas an inverse relationship was seen between the clustering of components and androgen levels in men (P < .001). For PAD, which could have a benign clinical course, early screening for MetS might identify those at greater risk of failing conservative therapy and progressing to a more aggressive atherosclerotic disease typically associated with high morbidity and mortality.
Ford ES, Giles WH, Dietz WHPrevalence of the metabolic syndrome among US healthy adults: findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.
2.
Ridker PM, Buring JE, Cook NR, Rifai N.C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthyAmerican women. Circulation. 2002;107: 391-397.
3.
Rantala AO, Kauma H., Lilja M., Savolainen MJ, Reunanen A., Kesaniemi YAPrevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects. J Intern Med. 1999;245:163-174.
4.
Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-689.
5.
Gorter PM, Olijhoek JK, van der Graaf Y., Algra A., Rabelink TJ, Visseren FL; SMART Study Group.Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Atherosclerosis. 2004;173:363-369.
6.
Dormandy JA, Rutherford RBManagement of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg.2000;31(1,pt2):S1-S296.
7.
Garcia LAEpidemiology and pathophysiology of lower extremity peripheral arterial disease . J Endovasc Ther.2006;13(suppl 2):113-119.
8.
Gottsäter A.Managing risk factors for atherosclerosis in critical limb ischemia. Eur J Vasc Endovasc Surg. 2006; 32:478-483.
9.
Murabito JM, D'Agostino RB, Silbershatz H., Wilson WFIntermittent claudication. A risk profile from the Framingham Heart Study . Circulation. 1997;96:44-49.
10.
Rutherford RB, Baker JD, Ernst C., et al. Recommended standards for reports dealing with lower extremity ischemia: revised version . J Vasc Surg. 1997;26:517-538.
11.
Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement . Circulation. 2005;112: 2735-2752.
12.
Migdalis IN , Kourti A., Zachariadis D., Voudouris G., Samartzis M.Peripheral vascular disease in newly diagnosed non-insulin-dependent diabetic. Int Angiol. 1992;11:230-232.
13.
Cardia G., Grisorio D., Impedovo G., Lillo A., Regina G.Plasma lipids as a risk factor in peripheral vascular disease. Angiology. 1990;41:19-22.
14.
Makin A., Lip GY, Silverman S., Beevers DGPeripheral vascular disease and hypertension: a forgotten association ? J Hum Hypertens. 2001;15:447-454.
15.
Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-2716.
16.
Isomaa B., Henricsson M., Almgren P., Tuomi T., Taskinen MR, Groop L.The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia. 2001;44:1148-1154.
17.
Trevisan M. , Liu J., Bahsas FB, Menotti A.Syndrome X and mortality: a population-based study. Risk Factor and Life Expectancy Research Group. Am J Epidemiol. 1998;148:958-966.
18.
Olijhoek JK , van der Graaf Y., Banga JD, Algra A., Rabelink TJ, Visseren FL; the SMART Study Group. The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm . Eur Heart J. 2004;25:342-348.
19.
Solymoss BC , Bourassa MG, Campeau L., et al. Effect of increasing metabolic score on atherosclerotic risk profile and coronary artery disease angiographic severity . Am J Cardiol. 2004 ;93:159-164.
20.
Ford ESThe metabolic syndrome and mortality from the cardiovascular diseases and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis. 2004;173: 309-314.
21.
Facchini F. , Chen YD, Hollenbeck CB, Reaven GMRelationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance and plasma uric acid concentration . JAMA. 1991;266:3008-3011.
22.
Gonzalez AS, Guerrero DB, Soto MB, Diaz SP, Martinez-Olmos M., Vidal O.Metabolic syndrome, insulin resistance and the inflammation markers c-reactive protein and ferritin. Eur J Clin Nutr. 2006 ;60:802-809.
23.
Muller M., Grobbee DE, den Tonkelaar I., Lamberts SW, van der Schouw YTEndogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab. 2005;90:2618-2623.
24.
Blouin K., Despres JP, Couillard C., et al. Contribution of age and declining androgen levels to features of the metabolic syndrome in men. Metabolism. 2005;54:1034-1040.
25.
Muller M., van den Beld AW, Bots ML, Grobbee DE, Lamberts SW, van der Schouw YTEndogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation. 2004;109:2074-2079.
26.
Dunajska K. , Milewicz A., Szymczak J., et al. Evaluation of sex hormone levels and some metabolic factors in men with coronary atherosclerosis . Aging Male. 2004:7:197-204.
27.
Culleton BF , Larson MG, Kannel WB, Levy D.Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study . Ann Intern Med. 1999;131:7-13.
28.
Rossi E., Biasucci LM, Citterio F., et al. Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: predictive role of C-reactive protein. Circulation. 2002;105:800-803.
29.
Langlois M. , De Bacquer D., Duprez D., De Buyzere M., Delanghe J., Blaton V.Serum uric acid in hypertensive patients with and without peripheral arterial disease. Atherosclerosis. 2003;168:163-168.
30.
Anker SD, Leyva F., Poole-Wilson PA, Kox WJ, Stevenson JC, Coats AJRelation between serum uric acid and lower limb blood flow in patients with chronic heart failure. Heart. 1997;78:39-43.
31.
Vainas T., Stassen FR, de Graaf R., et al. C-reactive protein in peripheral arterial disease: relation to severity of the disease and to future cardiovascular events. J Vasc Surg. 2005;42:243-251.
32.
Nguyen L., Liles DR, Lin PH, Bush RLHormone replacement therapy and peripheral vascular disease in women. Vasc Endovascular Surg. 2004;38:547-556.
Barani J., Mattiasson I., Lindblad B., Gottsater A.Suboptimal treatment of risk factor for atherosclerosis in critical limb ischemia . Int Angiol. 2005;24:59-63.
35.
Smith SC Jr, Allen J., Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113:2363-2372.
36.
Rice TW, Lumsden ABOptimal medical management of peripheral arterial disease. Vasc Endovasc Surg. 2006; 40:312-327.
